Spero Therapeutics is a biopharmaceutical company developing treatments for MDR bacterial infections and rare diseases. Product candidates include tebipenem pivoxil HBr for urinary tract infections, SPR206 for Gram-negative pathogens, and SPR720 for non-tuberculous mycobacterial pulmonary disease. The company has license agreements with Meiji Seika Pharma, Everest Medicines, and Vertex Pharmaceuticals to support development and commercialization of these products.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 0.7 |